Japanese Generics Makers Slow To Add Rep Staff To Boost Sales
This article was originally published in PharmAsia News
Executive SummaryGenerics makers may be missing the added sales encouraged by Japan's goal of 30 percent use, by short-staffing their sales forces. Makers of branded drugs still employ far more medical representatives than their generics rivals. Takeda Pharmaceutical has 2,000 while generics companies Towa Pharmaceutical and Sawai Pharmaceutical had only 420 and 341, respectively, at the end of March. (Click here for more - a subscription may be required
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.